Evidence map›Paper›PMID 27120167›Full record

ArticleNature2016

Continuous evolution of Bacillus thuringiensis toxins overcomes insect resistance.

Ahmed H Badran, Victor M Guzov, Qing Huai, Melissa M Kemp, Prashanth Vishwanath, Wendy Kain, Autumn M Nance, Artem Evdokimov, Farhad Moshiri, Keith H Turner and 3 more

Open access · greenAbstract read
In one paragraph

Article in Nature, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers.

0numbers the graph read from it
0cells of the map it votes in
117citing papers in PubMed
12.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

117 citing papers in PubMed, 205 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Targeted Transition Mutations in Phage-Assisted Evolution.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Functional redundancy in the toxic pathway of Bt protein Cry1Ab, but not Cry1Fa, against the Asian corn borer.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  17. EnhancingMicroorganisms · 2025
    Article
  18. Article
  19. Article
  20. Article

57 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Ahmed H BadranDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, USA.
Victor M GuzovMonsanto Company, 245 First Street, Suite 200, Cambridge, Massachusetts 02142, USA.
Qing HuaiMonsanto Company, 245 First Street, Suite 200, Cambridge, Massachusetts 02142, USA.
Melissa M KempMonsanto Company, 245 First Street, Suite 200, Cambridge, Massachusetts 02142, USA.
Prashanth VishwanathMonsanto Company, 245 First Street, Suite 200, Cambridge, Massachusetts 02142, USA.
Wendy KainDepartment of Entomology, Cornell University, Geneva, New York 14456, USA.
Autumn M NanceMonsanto Company, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017, USA.
Artem EvdokimovMonsanto Company, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017, USA.
Farhad MoshiriMonsanto Company, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017, USA.
Keith H TurnerMonsanto Company, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017, USA.
Ping WangDepartment of Entomology, Cornell University, Geneva, New York 14456, USA.
Thomas MalvarMonsanto Company, 700 Chesterfield Parkway West, Chesterfield, Missouri 63017, USA.
David R LiuDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, USA.
Monsanto (United States) · USCornell University · USHarvard University · USHoward Hughes Medical Institute · US

Funding

Continuous Evolution of Proteins with Novel Therapeutic PotentialR01EB022376 · NIBIB · HARVARD UNIVERSITY · PI LIU, DAVID R · 2016 to 2019
$1.8M
Howard Hughes Medical InstituteNIBIB NIH HHS R01 EB022376NIBIB NIH HHS R01EB022376
6 · The paper itself

Abstract

The Bacillus thuringiensis δ-endotoxins (Bt toxins) are widely used insecticidal proteins in engineered crops that provide agricultural, economic, and environmental benefits. The development of insect resistance to Bt toxins endangers their long-term effectiveness. Here we have developed a phage-assisted continuous evolution selection that rapidly evolves high-affinity protein-protein interactions, and applied this system to evolve variants of the Bt toxin Cry1Ac that bind a cadherin-like receptor from the insect pest Trichoplusia ni (TnCAD) that is not natively bound by wild-type Cry1Ac. The resulting evolved Cry1Ac variants bind TnCAD with high affinity (dissociation constant Kd = 11-41 nM), kill TnCAD-expressing insect cells that are not susceptible to wild-type Cry1Ac, and kill Cry1Ac-resistant T. ni insects up to 335-fold more potently than wild-type Cry1Ac. Our findings establish that the evolution of Bt toxins with novel insect cell receptor affinity can overcome insect Bt toxin resistance and confer lethality approaching that of the wild-type Bt toxin against non-resistant insects.

Indexed as

Insecticide ResistanceAmino Acid SequenceAnimalsBacillus thuringiensisBacillus thuringiensis ToxinsBacterial ProteinsBacteriophagesBiotechnologyCadherinsCell DeathConsensus SequenceCrops, AgriculturalDirected Molecular EvolutionEndotoxinsGenetic VariationHemolysin ProteinsBacillus thuringiensis ToxinsBacterial ProteinsCadherinsEndotoxinsHemolysin Proteinsinsecticidal crystal protein, Bacillus ThuringiensisInsecticides

Identifiers

PMID27120167
PMCPMC4865400
OpenAlexW2345218814

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.